allodynia with glp 1 and semaglutide: complete guide to GLP-1 skin pain ⚠️ New Sensory Side Effects

Consult our Seattle clinic for safe treatment

A new study published in April sheds light on the concerns of anesthesiologists across the United States related to the perioperative management of patients taking glucagon-like peptide-1 (GLP-1) agonists, a class of drugs now commonly prescribed for both diabetes and cosmetic weight loss

Our RDNs help you optimize results, reduce side effects & meet nutrition needs

PlexusDx providers evaluate your complete health history before prescribing

Each has demonstrated the potential to emerge as either a Best-in-Class or First-in-Class treatment in the obesity field.The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies. HM15275: Next-Generation Triple Agonist Targeting Quantity and Quality of Weight LossHM15275 is engineered to optimize the activity balance of GLP-1, GIP, and glucagon (GCG) receptors, delivering targeted obesity treatment while also addressing comorbid metabolic conditions such as diabetes, cardiovascular, and renal disease